<DOC>
	<DOCNO>NCT00001123</DOCNO>
	<brief_summary>The purpose test safety effectiveness intravenous ribavirin therapy person suspect subsequently prove hantavirus infection . The hantavirus spread air lung dry rodent feces move disturbed . It characterize fever bleed .</brief_summary>
	<brief_title>A Collaborative Double-Blind Placebo-Controlled Trial Intravenous Ribavirin As Treatment Presumed Hantavirus Pulmonary Syndrome</brief_title>
	<detailed_description>Patients randomize receive either ribavirin placebo 7 day . At completion therapy , patient see follow-up visit day 14 , 28 , 84 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hantavirus Pulmonary Syndrome</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>You may eligible study : Are 12 year age old . Are pregnant . Agree practice sexual abstinence use accept barrier method birth control/contraception . Are breastfeed . Have positive blood test hantavirus . Have symptom suggestive hantavirus illness . You eligible study : Have severe low blood count ( anemia ) . Have diagnosis respiratory virus ( influenza , RSV , etc. ) . Have group A Streptococcus symptoms streptococcal pharyngitis , positive culture normally sterile site , symptoms bacterial pneumonia . Are HIV positive . Have cancer . Have period irregular heartbeat . Have chemotherapy drug suppress immune system within 30 day . Have take mouth injection antiviral drug ( acyclovir , famciclovir , amantadine rimantadine . ) Have take mouth injection corticosteroid equivalent approximately 0.5 mg/kg prednisone . Have take experimental drug within 30 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
</DOC>